RxDoctor Payments Data

Cara Morgan, MD

Family Medicine · Jackson, MSNPI 1366477630

Payments from drug & device makers

$962in general payments, 2019–2025

Across 28 payments — averaging $34.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$293
  • Novo Nordisk$210
  • Abbott$196
  • Boehringer Ingelheim$132
  • Merck$43
  • Sanofi-aventis U.S. LLC$31
  • plus $57 from 4 others

What the payments were for

  • Food & beverage$962100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$962 in reported general payments places this provider in the 55th percentile of 971 family medicine providers in Mississippi.

See all family medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$5,301
Medicare patients
39
Services billed
85

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf)Adalimumab14$99,824
FarxigaDapagliflozin Propanediol78$98,388
JardianceEmpagliflozin42$67,982
OzempicSemaglutide35$66,967
TrulicityDulaglutide29$58,549
EliquisApixaban36$48,023
MounjaroTirzepatide20$41,988
RybelsusSemaglutide15$34,603
EntrestoSacubitril/Valsartan27$34,212
XareltoRivaroxaban24$26,968
Tresiba Flextouch U-100Insulin Degludec25$26,850
Soliqua 100-33Insulin Glargine/Lixisenatide17$24,211
Tresiba Flextouch U-200Insulin Degludec19$23,487
MyrbetriqMirabegron14$11,622
Lantus SolostarInsulin Glargine,hum.Rec.Anlog47$10,416

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$210$101,57050 claims
Lilly USA, LLCTrulicity, Mounjaro$16$100,53749 claims
AstraZenecaFarxiga$293$98,38878 claims
Boehringer IngelheimJardiance, Combivent Respimat$132$76,11555 claims
PfizerEliquis$12$48,02336 claims
Johnson & JohnsonXarelto$14$26,96824 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$31$24,21117 claims
GSKBreo Ellipta$15$9,06317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 971 family medicine providers in Mississippi.

Other family medicine in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →